Dexamphetamine increased speech and visual unimodal illusions in healthy participants without affecting temporal binding window
Human Psychopharmacology: Clinical and Experimental · 2024
DOI: 10.1002/hup.2896 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Human Psychopharmacology: Clinical and Experimental, 2024. Verfasst von Fui-Ling Voon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Biomedical Sciences, The University of Western Australia, Nedlands, Western Australia, Australia. Hauptthemen laut MEDLINE: Cross-Over Studies, Illusions, Dextroamphetamine, Visual Perception. Die Arbeit nennt 63 Literaturangaben.
Abstract (Originalsprache)
Objective
Stimuli received beyond a very short timeframe, known as temporal binding windows (TBWs), are perceived as separate events. In previous audio‐visual multisensory integration (McGurk effect) studies, widening of TBWs has been observed in people with schizophrenia. The present study aimed to determine if dexamphetamine could increase TBWs in unimodal auditory and unimodal visual illusions that may have some validity as experimental models for auditory and visual hallucinations in psychotic disorders.
Methods
A double‐blind, placebo‐controlled, counter‐balanced crossover design with permuted block randomisation for drug order was followed. Dexamphetamine (0.45 mg/kg, PO, q.d.) was administered to healthy participants. Phantom word illusion (speech illusion) and visual‐induced flash illusion/VIFI (visual illusion) tests were measured to determine if TBWs were altered as a function of delay between stimuli presentations. Word emotional content for phantom word illusions was also analysed.
Results
Dexamphetamine significantly increased the total number of phantom words/speech illusions ( p < 0.01) for pooled 220–1100 ms ISIs in kernel density estimation and the number of positive valence words heard (beta = 2.20, 95% CI [1.86, 2.55], t = 12.46, p < 0.001) with a large effect size (std. beta = 1.05, 95% CI [0.89, 1.22]) relative to placebo without affecting the TBWs. For the VIFI test, kernel density estimation for pooled 0–801 ms ISIs showed a significant difference ( p < 0.01) in the data distributions of number of target flash (es) perceived by participants after receiving dexamphetamine as compared with placebo.
Conclusions
Overall, healthy participants who were administered dexamphetamine (0.45 mg/kg, PO, q.d.) experienced increases in auditory and visual illusions in both phantom word illusion and VIFI tests without affecting their TBWs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Biomedical Sciences, The University of Western Australia, Nedlands, Western Australia, Australia.
- Faculty of Resources Science and Technology, Universiti Malaysia Sarawak, Kota Samarahan, Sarawak, Malaysia.
- Division of Psychiatry, Medical School, The University of Western Australia, Nedlands, Western Australia, Australia.
- North Metropolitan Health Service - Mental Health, Perth, Western Australia, Australia.
ORCID-Profile: Fui-Ling Voon
Zitieren
APA
Voon, F. L., Loffman, S. J., Lim, M. J. H., Lee, J. W. Y., Iyyalol, R., & Martin-Iverson, M. T. (2024). Dexamphetamine increased speech and visual unimodal illusions in healthy participants without affecting temporal binding window. Human Psychopharmacology: Clinical and Experimental. https://doi.org/10.1002/hup.2896
Vancouver
Voon FL, Loffman SJ, Lim MJH, Lee JWY, Iyyalol R, Martin-Iverson MT. Dexamphetamine increased speech and visual unimodal illusions in healthy participants without affecting temporal binding window. Human Psychopharmacology: Clinical and Experimental. 2024. doi:10.1002/hup.2896
BibTeX
@article{Voon2024,
author = {Voon, Fui-Ling and Loffman, Sean J and Lim, Mark J H and Lee, Joseph W Y and Iyyalol, Rajan and Martin-Iverson, Mathew T},
title = {Dexamphetamine increased speech and visual unimodal illusions in healthy participants without affecting temporal binding window},
journal = {Human Psychopharmacology: Clinical and Experimental},
year = {2024},
doi = {10.1002/hup.2896}
}
EUVIMED